Literature DB >> 15138135

Artificial liver support molecular adsorbents recirculating system therapy as a bridge to re-transplantation in two cases of long anhepatic duration.

Yi-He Liu1, Yu Wang, Li-Xin Yu, Li-Ying Sun, Bao-Lan Feng, Zhong-Yang Shen, Min-Min Wang.   

Abstract

BACKGROUND: Molecular adsorbents recirculating system (MARS) liver support therapy is the development of albumin dialysis. This study was to assess the successful application of MARS artificial liver support therapy as a bridge to re-transplantation in two cases of long anhepatic duration.
METHODS: MARS therapy was given after failure plasma-exchange (PE) treatment, which resulted in circulatory derangement and acute renal dysfunction in a 36-year-old male patient. Finally his uncontrolled anhepatic condition led to a successful re-transplantation. In another 48-year-old man who was diagnosed as having primary nonfunction (PNF) during the liver transplantation, 10-hour MARS treatment contributed to smooth bridging of his anhepatic phase.
RESULTS: The two anhepatic patients were bridged for 26 and 17 hours respectively to re-transplantation with MARS therapy.
CONCLUSION: Our experience proves that MARS artificial liver can be an effective support for long time bridging PNF until re-transplantation is available.

Entities:  

Mesh:

Year:  2004        PMID: 15138135

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  4 in total

1.  MARS therapy, the bridging to liver retransplantation - Three cases from the Hungarian liver transplant program.

Authors:  Balázs Pőcze; János Fazakas; Gergely Zádori; Dénes Görög; László Kóbori; Eszter Dabasi; Tamás Mándli; László Piros; Anikó Smudla; Tamás Szabó; Eva Toronyi; Szabolcs Tóth; Gellért Tőzsér; Gyula Végső; Attila Doros; Balázs Nemes
Journal:  Interv Med Appl Sci       Date:  2013-07-04

2.  Heparin-induced thrombocytopenia associated with acute liver graft failure.

Authors:  Nadine Pannicke; Joerg-Matthias Pollok; Stefan Kluge; Martin Petzoldt
Journal:  BMJ Case Rep       Date:  2012-11-27

3.  Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center.

Authors:  Clément Monet; Audrey De Jong; Yassir Aarab; Lauranne Piron; Albert Prades; Julie Carr; Fouad Belafia; Gérald Chanques; Boris Guiu; Georges-Philippe Pageaux; Samir Jaber
Journal:  Crit Care       Date:  2022-09-19       Impact factor: 19.334

4.  Transplant Hepatectomy With Portacaval Shunt and MARS Therapy for Perioperative Catastrophe: A Series of Four Liver Transplant Cases.

Authors:  Arielle Cimeno; Samuel Sultan; Josue Alvarez-Casas; Steven I Hanish; David A Bruno; William R Hutson; Deborah M Stein; Thomas M Scalea; Rolf N Barth; John C LaMattina
Journal:  Transplant Direct       Date:  2021-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.